Differentiated expression of somatostatin receptor subtypes in experimental models and clinical neuroblastoma

2010 ◽  
Vol 56 (4) ◽  
pp. 584-589 ◽  
Author(s):  
Kleopatra Georgantzi ◽  
Apostolos V. Tsolakis ◽  
Mats Stridsberg ◽  
Åke Jakobson ◽  
Rolf Christofferson ◽  
...  
Keyword(s):  
Somatostatin Receptor ◽  
Experimental Models ◽  
Receptor Subtypes ◽  
Somatostatin Receptor Subtypes

scholarly journals 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5

2004 ◽  
Vol 32 (6) ◽  
pp. 724-724 ◽  
Author(s):  
Damian Wild ◽  
Helmut R. Mäcke ◽  
Beatrice Waser ◽  
Jean Claude Reubi ◽  
Mihaela Ginj ◽  
...  
Keyword(s):  
Pet Imaging ◽  
Somatostatin Receptor ◽  
Receptor Subtypes ◽  
High Affinity ◽  
Somatostatin Receptor Subtypes

Prognostic Value of Somatostatin Receptor Subtypes in Pancreatic Neuroendocrine Tumors

Pancreas ◽  
2016 ◽  
Vol 45 (2) ◽  
pp. 187-192 ◽  
Author(s):  
Ki Byung Song ◽  
Song Cheol Kim ◽  
Ji Hun Kim ◽  
Dong-Wan Seo ◽  
Seung-Mo Hong ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Prognostic Value ◽  
Somatostatin Receptor ◽  
Receptor Subtypes ◽  
Pancreatic Neuroendocrine Tumors ◽  
Somatostatin Receptor Subtypes

scholarly journals Expression of Somatostatin Receptor 2 in Somatotropinoma Correlated with the Short-Term Efficacy of Somatostatin Analogues

2017 ◽  
Vol 2017 ◽  
pp. 1-7 ◽  
Author(s):  
Wenjuan Liu ◽  
Lina Xie ◽  
Min He ◽  
Ming Shen ◽  
Jingjing Zhu ◽  
...  
Keyword(s):  
Tumor Size ◽  
Tumor Volume ◽  
Somatostatin Receptor ◽  
Somatostatin Analogues ◽  
Receptor Subtypes ◽  
Short Term ◽  
Pituitary Growth Hormone ◽  
Term Efficacy ◽  
Somatostatin Receptor Subtypes ◽  
Pretreated Group

The expression of somatostatin receptor subtypes (SSTRs) in pituitary growth hormone- (GH-) secreting adenomas may predict the response to somatostatin analogues (SSA). Our aim was to evaluate the value of the immunohistochemical (IHC) scores of 2 subtypes, SSTR2 and SSTR5, in predicting the short-term efficacy of SSA therapy in patients with active acromegaly. Ninety-three newly diagnosed acromegalic patients were included in our study. These patients were categorized into either a SSA-pretreated group (SA, n=63) or a direct-surgery group (DS, n=30), depending on whether or not presurgical SSA treatment was received. IHC analysis, using a 12-grade scoring system, with rabbit monoclonal antibodies against SSTR2 and SSTR5, was performed on all adenoma tissues. The reduction of GH, IGF-1, and tumor size after treatment with SSA for 3 months was measured. Compared with that in the DS group, SSTR2 expression was lower in the SA group. Additionally, in the SA group, SSTR2 expression was positively correlated with the reduction of IGF-1 and tumor volume. However, there was no correlation between the SSTR5 score and the efficacy of SSA. In conclusion, the protein expression of SSTR2, but not of SSTR5, is a valuable indicator in predicting biochemical and tumor size response to short-term SSA treatment in acromegalic patients.

Role of Somatostatin Receptor Subtypes in Acromegaly

2005 ◽  
Vol 15 (6) ◽  
pp. 377-383 ◽  
Author(s):  
Joost van Der Hoek ◽  
Steven W. J. Lamberts ◽  
Leo J. Hofland
Keyword(s):  
Somatostatin Receptor ◽  
Receptor Subtypes ◽  
Somatostatin Receptor Subtypes
Sign in / Sign up

Export Citation Format

Share Document